MyoKardia Inc. priced an underwritten public offering of 3,750,000 common shares at $49 each.
Underwriters have a 30-day option to buy up to an additional 562,500 shares on the same terms and conditions.
The company plans to use net proceeds on its development programs, as well as working capital and general corporate purposes.
J.P. Morgan Securities, Bank of America Merrill Lynch, Credit Suisse and Wells Fargo Securities are joint book-running managers for the offering.
South San Francisco-based MyoKardia develops treatments for rare cardiovascular diseases.
